GSK’s (GSK) “Buy” Rating Reiterated at Jefferies Financial Group

Jefferies Financial Group reiterated their buy rating on shares of GSK (LON:GSK) in a research report report published on Wednesday,Digital Look reports. Jefferies Financial Group currently has a GBX 2,500 price objective on the stock.

A number of other research analysts have also recently commented on GSK. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a GBX 1,950 target price on shares of GSK in a research note on Monday, July 27th. Citigroup dropped their price target on GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. Two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of GBX 2,041.43.

GSK Trading Down 0.4%

Shares of GSK stock opened at GBX 1,931.50 on Wednesday. The company has a debt-to-equity ratio of 103.36, a current ratio of 0.82 and a quick ratio of 0.73. GSK has a 1 year low of GBX 1,288.61 and a 1 year high of GBX 2,282. The firm has a market cap of £77.37 billion, a PE ratio of 13.59, a PEG ratio of 1.24 and a beta of 0.30. The company has a 50 day simple moving average of GBX 1,938.84 and a two-hundred day simple moving average of GBX 1,991.45.

GSK (LON:GSK) last issued its quarterly earnings results on Tuesday, July 28th. The company reported GBX 10.80 EPS for the quarter. GSK had a net margin of 14.52% and a return on equity of 28.35%. Analysts expect that GSK will post 175.980975 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Jonathan Symonds acquired 1,550 shares of the stock in a transaction on Friday, June 19th. The stock was purchased at an average price of GBX 1,935 per share, for a total transaction of £29,992.50. Also, insider Vishal Sikka acquired 1,266 shares of the company’s stock in a transaction dated Monday, June 22nd. The shares were bought at an average cost of GBX 5,069 per share, with a total value of £64,173.54. In the last 90 days, insiders acquired 3,625 shares of company stock valued at $13,495,004. Corporate insiders own 0.20% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.